Avicanna Inc. - CEO, Aras Azadian
CEO, Aras Azadian
Source: Finance Colombia
Market Herald logo


Be the first with the news that moves the market
  • Avicanna (TSX:AVCN) has signed an importation and distribution agreement with Australia-based Cannavalate Pty Ltd
  • The deal will enable the supply of Avicanna’s Rho Phyto™ products under the Australian Therapeutic Goods Special Access Scheme
  • The company will also supply Cannavalate with a white-label line of advanced cannabinoid phyto-therapeutic products
  • Avicanna’s products are expected to be manufactured in Colombia before being sent to Australia
  • Shares in the company are currently down 4.32 per cent to C$1.77, with a market cap of C$38.91 million

Avicanna (TSX:AVCN) has signed an importation and distribution agreement with Cannavalate Pty Ltd.

Cannavalate is the largest end-to-end solution provider for Licensed Producers looking to initiate growth in the Australian market.

Under the agreement, Avicanna will supply its Rho Phyto™ products to Cannavalate in accordance with the Australian Therapeutic Goods Special Access Scheme.

The company will also supply various pharmaceutical ingredients and advanced cannabinoid phyto-therapeutic products on a white-label basis.

“After significant due diligence into the Australian market and its operators we are pleased to be able to introduce Cannvalate as our partners in the region,” said Avicanna CEO, Aras Azadian.

“Our two companies are aligned on a strictly medical approach backed by sustainable processes, data driven R&D and clinical development which will be to the benefit of the Australian patients and medical community at large.”

Cannavalate will act as an exclusive distributor, but will remain subject to minimum purchase requirements.

“We are delighted to assist Avicanna with market entry to Australia which is one of the fastest growing pureplay medicinal cannabis markets globally,” said Cannavalate CEO, Sud Agarwal.

“We look forward to assisting Avicanna with meeting the stringent Office of Drug Control testing requirements and designing TGA-compliant physician education/ detailing campaigns.”

It’s expected that the products will be manufactured at the facilities of Avicanna’s exclusive Colombian partner, Altea Farmaceutica S.A. before shipping to Australia.

Originally developed and optimized in Canada, the products will use extracts from Santa Marta Golden Hemp S.A.S., a subsidiary of Avicanna.

Shares in the company are currently down 4.32 per cent to C$1.77, with a market cap of C$38.91 million.

More From The Market Herald

The Market Herald’s Weekly Cannabis Report – Sept. 29, 2023

A U.S. Senate committee has approved The Secure and Fair Enforcement Regulation Banking Act (SAFER) for a vote on the Senate floor.

Jones Soda brings cannabis brand Mary Jones to Washington State

Jones Soda (CSE:JSDA) announced that its crossover cannabis brand, Mary Jones, is now available at dispensaries in Washington state.

MediPharm Labs boosts Australian presence with new products

MediPharm Labs (TSX:LABS) is debuting its GMP-certified cannabis oil and inhalation cartridges in the Australian medical market.

Cannabis stocks retreat as SAFER Banking Act moves to Senate

The U.S. SAFER Banking act would grant cannabis stocks access to traditional banking, including credit, loans and financial services.